This stock is ultra-cheap, and should rebound nicely when investors stop sprinting away from tech stocks. If you’ve got a strong stomach, this is a great time to be buying tech. Dendreon’s Costly Problem Biotech firm Dendreon (Nasdaq: …
According to our database of 13F filings, it had not owned any equity in the company at the end of September (see its top stock picks here). Dendreon's market capitalization is only about $870 million, but on average, more than 4 million …
Mitchell Gold, President and CEO of Dendreon Corporation (DNDN), will visit NASDAQ MarketSite in Times Square …
We don't think a short idea in the name is relevant today, either. We checked around to find out if one could borrow DNDN stock. We are told there is a -9.95% rebate on anything above 200,000 shares. Last quarter, DNDN announced more …
Friday it will pay for a greater number of patients to receive Provenge, a prostate cancer drug made by Dendreon Corp, sending Dendreon's shares up as much as 10 percent.
But a little less than every once in a while, DNDN makes the medical news with a carcinoembryonic antigen, a carbonic anhydrase or a new small molecule, and its stock price will spike. A promising cancer drug that got Food and Drug …
Chiang spells out “The Good” for the giant: “In our view, management closing the …
Dendreon (DNDN) stock fell 20% in afternoon trading after saying in its fourth quarter earnings report that sales of its prostate cancer drug Provenge have been weak in the first quarter. Sales of Provenge could rise in the low single digits …
Seattle-based biotech company Dendreon (DNDN) announced there was “significant risk” it would not be able to pay off its $620 million debt. As a result of that statement, stock shares dropped 20% to $1.67 in premarket trade Tuesday. It …
Dendreon Corporation (NASDAQ: DNDN) climbed up 4.26% over its previous day’s price and now trades at $28.88 on a massive volume of 1.10 million shares. The stock has a 52-week range of $2.55-$30.90. Dendreon Corporation …